Breathe Well Live Well
|
Tiotropium beneficial as add-on for poorly controlled asthma
Healio Gustavo J. Rodrigo, MD, of the Hospital Central de las Fuerzas Armadas in Uruguay, and a colleague reviewed 13 randomized controlled trials that included 4,966 patients to assess the efficacy and safety of tiotropium bromide in patients with asthma. |
View full post on asthma – Google News
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: tiotropium; Device: Handihaler; Device: Respimat
Sponsor: University of Crete
Completed – verified January 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Tiotropium Showing Promise in Pediatric Asthma
Medscape AUSTIN — In children with poorly controlled asthma, once-daily tiotropium delivered with the Respimat inhaler improves lung function when added to inhaled corticosteroids, with no apparent change in adverse effects, new research has shown. The drug … |
View full post on asthma – Google News
Condition: Healthy
Interventions: Drug: Tiotropium/Salmeterol; Drug: Serevent® Diskus®; Drug: Spiriva®
Sponsor: Boehringer Ingelheim
Completed – verified September 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Tiotropium Complements Steroids in Treatment of Asthma
Medscape To see whether inhaled tiotropium could improve symptoms in patients with mild asthma who are already using steroids, the researchers randomly assigned 155 patients to inhale 5.0 µg/day, 154 to inhale 2.5 µg/day, and 155 to inhale a placebo. Patients … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
Drug Discovery & Development Boehringer Ingelheim announced new data from large scale, Phase 3 studies showing that once-daily tiotropium delivered via the Respimat inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the … Tiotropium as Asthma Add-On Treatment Shows Promise |
View full post on asthma – Google News
|
Tiotropium as Asthma Add-On Treatment Shows Promise
Monthly Prescribing Reference Boehringer Ingelheim has announced positive results from several Phase 3 studies analyzing once-daily tiotropium (Spiriva; Boehringer Ingelheim) delivered via the Respimat inhaler as an add-on treatment for asthma patients who remain symptomatic with … Phase III studies show tiotropium delivered via Respimat inhaler proves … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
PR Newswire (press release) RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ — Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat® inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, … |
View full post on asthma – Google News
|
Phase III studies show tiotropium delivered via Respimat inhaler proves …
News-Medical.net Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at … |
View full post on asthma – Google News
|
ASTHMA: New Phase III data show tiotropium * Respimat ® effective across …
Business Wire (press release) Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at … |
View full post on asthma – Google News